RAPSODI
"PRe-clinicAl studies of a PSA-based human vaccine candidate targeting visceral, cutaneOus and mucocutaneous Leishmaniasis and Development of the associated procedures for further clinical trials"
| Coordinatore | VIRBAC SA
Organization address
address: RUE 13EME LID contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 4˙004˙911 € |
| EC contributo | 2˙737˙149 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-SICA |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-01-01 - 2012-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
VIRBAC SA
Organization address
address: RUE 13EME LID contact info |
FR (CARROS) | coordinator | 565˙024.60 |
| 2 |
INSTITUTO DE SALUD CARLOS III
Organization address
address: CALLE SINESIO DELGADO 4-6 contact info |
ES (MADRID) | participant | 554˙300.80 |
| 3 |
UNIVERSIDAD PERUANA CAYETANO HEREDIA
Organization address
address: HONORIO DELGADO 430 contact info |
PE (LIMA) | participant | 444˙351.70 |
| 4 |
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
Organization address
address: Boulevard de Dunkerque - CS 90009 44 contact info |
FR (MARSEILLE) | participant | 404˙093.00 |
| 5 |
Indian Council of Medical Research
Organization address
address: Ansari Nagar contact info |
IN (New Delhi) | participant | 330˙840.00 |
| 6 |
INSTITUT PASTEUR DE TUNIS
Organization address
address: Place Pasteur 13 contact info |
TN (TUNIS) | participant | 300˙175.70 |
| 7 |
ALMA CONSULTING GROUP SAS
Organization address
address: Domaine des Bois d'Houlbec contact info |
FR (HOULBEC COCHEREL) | participant | 90˙680.00 |
| 8 |
SYNCROSOME SAS
Organization address
address: AVENUE DE LUMINY - LUMINY BIOTECH CP 908 163 contact info |
FR (MARSEILLE) | participant | 43˙183.20 |
| 9 |
INSTIMED
Organization address
city: Saint Pierre des Corps contact info |
FR (Saint Pierre des Corps) | participant | 4˙500.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The global aim of RAPSODI is : · to develop a human vaccine candidate against most or all Leishmania species that cause the most severe leishmaniasis in the world. An unique vaccinal solution will thus be provided to protect against the various clinical phenotypes (namely visceral, cutaneous and mucocutaneaous leishmaniasis, VL, CL and ML respectively). · to establish all the associated procedures required for the subsequent clinical trials, such as the selection of the appropriate patients and assessment of vaccine efficiency. For that purpose, an international consortium constituted of countries from endemic areas (India, Peru, Tunisia, Spain and France) and embracing multi-disciplinary approaches has been set-up. Based on successful results on VL dogs, the best VL animal model to date, RAPSODI will propose a second generation human-compatible vaccine candidate and confirm its activity in pre-clinical studies. As the chosen antigen is common to most, if not all, Leishmania species, an ambitious universal immunoprotective response is being sought. RAPSODI will also address the question of population selection in order to ascertain relevant and meaningful clinical trials and vaccination campaigns. Indeed, resistant individuals, when involved in either vaccinated or placebo groups, represent important bias to the analysis of the results. RAPSODI will investigate further the parasitological, immunological and genetic features of such clinical status, and will subsequently apply the generated knowledge to the development of assays and field tests, which represent stand-alone results. The package (vaccine candidate diagnostic/prognostic tools) proposed by RAPSODI represents a global solution, and as such is believed to have a real impact on the worldwide leishmaniasis problem.'